
Azacitidine and nivolumab combo proves successful in phase II trial
pharmafile | November 13, 2018 | News story | Manufacturing and Production | Cancer, leukaemia, opdivo, pharma, texas
A combination of chemotherapy drug azacitidine and nivolumab (Bristol-Myers Squibb’s Opdivo) has proven effective in treating patients with relapsed or refractory acute myeloid leukaemia (AML) in a phase II trial, led by Professor Naval Daver the University of Texas MD Anderson Cancer Center.
The phase II trial demonstrated that 22% of the 70 patients went into complete remission following the combination treatment. While participants had on average already undergone two prior treatments for relapsed AML, the response rate was 33% overall.
However around 11% of patients suffered from severe or potentially life threatening side effects, the majority of which were treated successfully. The average overall survival was just over 6 months. Due to the encouraging results, researchers have initiated a phase III trial.
Daverat commented: “We believe that implementation of clinical and immune biomarkers to select patients are likely to yield further improved outcomes with these types of therapies in AML.
Louis Goss
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …






